Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
Market Closed
Updated:
May 14, 2024
Fusion Antibodies PLC
Additional Paid In Capital
|
Fusion Antibodies PLC
Additional Paid In Capital Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Additional Paid In Capital
£8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Additional Paid In Capital
£698.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Additional Paid In Capital
£4k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Additional Paid In Capital
£37.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
227%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Additional Paid In Capital
£1m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Additional Paid In Capital
£516k
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-17%
|
See Also
What is Fusion Antibodies PLC's Additional Paid In Capital?
Additional Paid In Capital
8m
GBP
8m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Additional Paid In Capital amounts to 8m GBP.
What is Fusion Antibodies PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
10%
10%
Over the last year, the Additional Paid In Capital growth was 4%. The average annual Additional Paid In Capital growth rates for Fusion Antibodies PLC have been 2% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
